UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
prostate cancer (9102) 9102
humans (7347) 7347
male (7195) 7195
science & technology (7070) 7070
life sciences & biomedicine (6594) 6594
oncology (4673) 4673
cancer (3710) 3710
metastasis (3182) 3182
research (2833) 2833
prostatic neoplasms - pathology (2520) 2520
prostatic neoplasms - drug therapy (2454) 2454
care and treatment (2374) 2374
androgens (2048) 2048
aged (1944) 1944
prostatic neoplasms, castration-resistant - drug therapy (1904) 1904
urology & nephrology (1885) 1885
animals (1877) 1877
cell line, tumor (1876) 1876
middle aged (1668) 1668
prostatic neoplasms - metabolism (1595) 1595
cancer therapies (1572) 1572
prostate (1526) 1526
chemotherapy (1523) 1523
oncology, experimental (1377) 1377
prostatic neoplasms, castration-resistant - pathology (1247) 1247
treatment outcome (1238) 1238
prostatic neoplasms - genetics (1232) 1232
antineoplastic agents - therapeutic use (1206) 1206
tumors (1206) 1206
analysis (1130) 1130
urology (1114) 1114
mice (1088) 1088
development and progression (1084) 1084
health aspects (1038) 1038
aged, 80 and over (1036) 1036
drug therapy (1009) 1009
receptors, androgen - metabolism (929) 929
gene expression (899) 899
clinical trials (894) 894
prognosis (889) 889
castration (878) 878
disease progression (842) 842
apoptosis (817) 817
metastases (814) 814
androgen antagonists - therapeutic use (803) 803
patients (802) 802
neoplasm metastasis (799) 799
genetic aspects (763) 763
proteins (743) 743
prostate-specific antigen - blood (732) 732
medical research (728) 728
docetaxel (719) 719
endocrinology & metabolism (713) 713
prostatic neoplasms - therapy (705) 705
cell biology (700) 700
physical fitness (678) 678
androgen receptor (668) 668
medicine (646) 646
bone neoplasms - secondary (644) 644
castration-resistant prostate cancer (644) 644
antineoplastic agents - pharmacology (642) 642
phenylthiohydantoin - analogs & derivatives (627) 627
immunotherapy (619) 619
antineoplastic combined chemotherapy protocols - therapeutic use (615) 615
receptors, androgen - genetics (614) 614
antigens (611) 611
signal transduction (606) 606
cell proliferation - drug effects (603) 603
taxoids - therapeutic use (601) 601
gene expression regulation, neoplastic (590) 590
urologic and male genital diseases (589) 589
prostatic neoplasms, castration-resistant - metabolism (582) 582
orchiectomy (550) 550
research article (548) 548
kinases (542) 542
medicine & public health (537) 537
studies (531) 531
pharmacology & pharmacy (529) 529
disease-free survival (525) 525
retrospective studies (523) 523
drug resistance, neoplasm (511) 511
prostatic neoplasms, castration-resistant - genetics (504) 504
biochemistry & molecular biology (496) 496
biomarkers (495) 495
xenograft model antitumor assays (495) 495
signal transduction - drug effects (489) 489
medical prognosis (488) 488
antineoplastic agents (487) 487
science & technology - other topics (483) 483
cell proliferation (466) 466
review (466) 466
multidisciplinary sciences (460) 460
apoptosis - drug effects (455) 455
mice, nude (448) 448
prostatic neoplasms - mortality (446) 446
antimitotic agents (441) 441
neoplasms. tumors. oncology. including cancer and carcinogens (439) 439
taxoids - administration & dosage (435) 435
risk factors (428) 428
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11115) 11115
Japanese (61) 61
German (60) 60
French (39) 39
Spanish (26) 26
Chinese (22) 22
Norwegian (7) 7
Hungarian (6) 6
Russian (5) 5
Italian (4) 4
Czech (3) 3
Danish (3) 3
Portuguese (3) 3
Dutch (2) 2
Turkish (2) 2
Afrikaans (1) 1
Hebrew (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 02/2014, Volume 65, Issue 2, pp. 270 - 273
Journal Article
Nature (London), ISSN 1476-4687, 03/2017, Volume 543, Issue 7647, pp. 728 - 732
A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC)(1... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Anilides - therapeutic use | Immunotherapy - methods | Humans | Prostatic Neoplasms, Castration-Resistant - immunology | Male | Myeloid-Derived Suppressor Cells - drug effects | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - pathology | Quinolines - pharmacology | Myeloid-Derived Suppressor Cells - cytology | Prostatic Neoplasms, Castration-Resistant - therapy | Female | Imidazoles - therapeutic use | Cytokines - immunology | Disease Models, Animal | Pyridines - therapeutic use | Tumor Microenvironment - drug effects | Myeloid-Derived Suppressor Cells - immunology | Cytokines - metabolism | Imidazoles - pharmacology | Lymphocytes, Tumor-Infiltrating - drug effects | Drug Synergism | Tumor Microenvironment - immunology | Animals | Signal Transduction - drug effects | CD8-Positive T-Lymphocytes - drug effects | Anilides - pharmacology | Mice | Pyridines - pharmacology | Quinolines - therapeutic use | CD8-Positive T-Lymphocytes - immunology | Chimera | Lymphocytes, Tumor-Infiltrating - immunology | Care and treatment | Metastasis | Prostate cancer | Analysis | Immunotherapy | Patient outcomes | Cancer therapies | Tumors | Index Medicus
Journal Article
European urology, ISSN 0302-2838, 02/2017, Volume 71, Issue 2, pp. 151 - 154
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 700 - 712
Journal Article
European urology, ISSN 0302-2838, 11/2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer | Index Medicus
Journal Article
The Journal of clinical investigation, ISSN 1558-8238, 12/2018, Volume 129, Issue 2, pp. 569 - 582
Prostate cancer (PC) progressed to castration resistance (CRPC) is a fatal disease. CRPC tumors develop resistance to new-generation antiandrogen enzalutamide... 
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Oligonucleotide Array Sequence Analysis | Transforming Growth Factor beta3 - genetics | Humans | Male | Neoplasm Proteins - antagonists & inhibitors | Receptor, Transforming Growth Factor-beta Type I - antagonists & inhibitors | Gene Expression Profiling | Hepatocyte Nuclear Factor 3-alpha - antagonists & inhibitors | Neoplasm Proteins - metabolism | Transforming Growth Factor beta3 - metabolism | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Quinolines - pharmacology | Receptor, Transforming Growth Factor-beta Type I - metabolism | Neoplasm Proteins - genetics | Pyrazoles - pharmacology | Signal Transduction | Hepatocyte Nuclear Factor 3-alpha - genetics | Prostatic Neoplasms, Castration-Resistant - drug therapy | Mice, SCID | Prostatic Neoplasms, Castration-Resistant - metabolism | Hepatocyte Nuclear Factor 3-alpha - metabolism | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Mice | Receptor, Transforming Growth Factor-beta Type I - genetics | Phosphorylation | Motility | Mesenchyme | Genomics | Genomes | Metastasis | Kinases | Metastases | Proteins | Disease resistance | Liver cancer | Genotype & phenotype | Cell growth | Castration | Smad2 protein | Cooperation | Xenografts | Plasticity | Bioinformatics | Growth factors | Phenotypes | Transforming growth factor-b1 | Gene expression | Studies | Androgens | DNA microarrays | Pheochromocytoma cells | Prostate cancer | Prostate | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 04/2016, Volume 34, Issue 12, pp. 1402 - 1418
Journal Article
Journal Article